August 17, 2020
Philips Introduces OmniWire in the United States and Japan
August 17, 2020—Royal Philips announced the introduction of OmniWire, a solid core pressure wire for coronary artery interventional procedures. OmniWire has received FDA clearance and approval from the Japan Pharmaceuticals and Medical Devices Agency and is now commercially available in the United States and Japan.
According to Philips, the new wire supports instant wave-free ratio (iFR) measurements and fractional flow reserve measurements. It also integrates with the Philips IntraSight interventional applications platform, which can coregister iFR data onto the angiogram to precisely identify the parts of vessels requiring treatment.
OmniWire uses advanced conductive ribbons embedded in its outer polymer layer to communicate pressure information. The distal part of the wire is made from nitinol, and the proximal part of the wire is constructed from a cobalt alloy that provides high durability for complex and multivessel cases.
With its solid core construction, in contrast to a hollow metal hypotube, the OmniWire device allows physicians to more easily maneuver the wire in the patient’s circulatory system to measure blood pressure along the vessel and guide the delivery of catheters and stents, stated the company.
The first human case with the OmniWire in the United States was performed by Jasvindar Singh, MD, Director of the Catheterization Lab at Barnes Jewish Hospital and Associate Professor at Washington University in St. Louis, Missouri.
“I have been very impressed with the handling of OmniWire; the new solid core design performed beautifully, and I was able to navigate the difficult case easily,” commented Dr. Singh in the company’s announcement. “We used iFR coregistration and found that the patient needed a stent. I was then able to perform the whole procedure working over OmniWire. This is truly an innovation in percutaneous coronary interventions.”